VIDAS^® SARS-COV-2

Severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) is a novel coronavirus discovered in China in December 2019 that has led to an unprecedented global pandemic. It causes coronavirus disease 19 (COVID‑19), a respiratory illness with symptoms ranging from mild to severe with possible progression to pneumonia, multiorgan failure and even to death. Identification of individuals who have been infected by this new virus is key for better management of the patients and to face the COVID-19 health crisis.

VIDAS^® SARS-COV-2 IgM (9COM) and VIDAS^® SARS-COV-2 IgG (9COG) use a two-step sandwich enzyme immunoassay method with a final fluorescence detection (ELFA). For use on any VIDAS^® instrument, they offer flexibility and reliability for results in less than 30 minutes.

VIDAS^® SARS-COV-2 advantages

• Single dose automated tests for greater flexibility
• All-inclusive, small-size kits
  
  • Security and simplicity with less handling
  • Long shelf life (12 months) and easy storage
  • Reagents ready-to-use in sealed, single-use strips
• Two tests with same protocols to differentiate IgM & IgG results:
  
  • VIDAS^® SARS-COV-2 IgM to detect IgM specific for SARS-CoV-2
  • VIDAS^® SARS-COV-2 IgG to detect IgG specific for SARS-CoV-2

Rapid results you can count on

• Available on-demand 24/7 on all VIDAS^® platforms
• Reliable results in less than 30 minutes
• Performance with high specificity and sensitivity from day 8
• Results help provide additional pandemic analysis data

Ease of use on any VIDAS^® instrument

• Automated ELFA technology
• All assay steps performed automatically by instrument
• Intuitive and easy to use
• Limited maintenance, calibration & controls